Shanghai Cell Therapy Group raised $136 million in a C round. Established in 2000, the company is a precision medicine company, offering cancer diagnosis and treatment, plus services that include cell production, cell cryopreservation, genetic testing and cell-related products. It is also constructing a clinical medical database, and it has established the Shanghai Wu Mengchao-Nobel Laureate Joint Medical Technology and Innovation Center. The funding was led by China Pacific Insurance, Haier Capital and China Industrial Asset Management.
Source: China Biotoday
